EUCTR2005-003630-18-DE进行中（未招募）不适用
Phase 3, randomized, investigator-blind, multi-center study to evaluate efficacy and safety of intravenous iclaprim versus intravenous linezolid in complicated skin and skin structure infections - ASSIST-2
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Arpida AG
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Hospitalized with clinical evidence of at least 1 of the following:
- •a)Infected ulcers,
- •b)First or second degree burns of less than 20% of body surface area with concomitant signs of cellulitis (excluding third degree burns and burns >20% of body surface area),
- •c)Major abscess (see exclusion criteria for important qualifications),
- •d)Deep or extensive cellulitis, and/or
- •e)Wound infections.
- •2.Presence of purulent or seropurulent drainage or at least 3 of the following signs and symptoms:
- •a)Drainage and/or discharge,
- •b)Erythema (extending at least 1 cm beyond a wound edge),
- •c)Swelling and/or induration,
- •d)Heat and/or localized warmth, and/or
- •e)Pain and/or tenderness to palpation.
- •3.At least 1 of the following conditions considered to be pathogen-related:
- •·Fever (temperature >38°C/100.4°F orally, rectally, or tympanically),
- •·Elevated total peripheral white blood cells (WBCs) >10,000/mm3, or
- •·>15% immature neutrophils (bands), regardless of total peripheral WBC count.
- •4.Accessible infection site for culture;
- •5.At least 18 years of age;
- •6.Written informed consent to participate in the study before any study-specific screening procedures are performed. If any patient is unable to give consent, it may be obtained from the patient’s next of kin or legally acceptable representative in accordance with local laws and regulations.
- •7.If female, must either:
- •7a. be post-menopausal for at least 1 year;or
- •7b. have had a hysterectomy or tubal ligation;or
- •7c. if of childbearing potential have maintained her normal menstrual pattern for the 3 months prior to study entry, and have taken hormonal contraceptives for at least 1 month prior to study entry;or
- •7d. if of childbearing potential agree to use spermicide and barrier methodsor
- •7e. if of childbearing potential be using another medically acceptable method of contraception and agrees to continue with the same method during the study;
- •has a negative serum pregnancy test (serum beta-human chorionic gonadotropin [hCG]) result immediately prior to enrollment. If obtaining the serum pregnancy result would cause a delay in treatment, the patient can be entered on the basis of a negative urine pregnancy test result. The urine pregnancy test must be sensitive to at least 50 mU/mL of beta-hCG, pending results of the serum test. The patient must end study medication therapy if the serum pregnancy test is positive.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.cSSSIs of the following categories:
- •a)Severely impaired arterial blood supply such that amputation of the infected anatomical site is likely,
- •b)Infected diabetic foot ulcers or decubitus ulcers,
- •c)Infected human or animal bites,
- •d)Necrotizing fasciitis or gangrene,
- •e)Uncomplicated skin or skin structure infection (e.g., simple abscesses, folliculitis, impetiginous lesions, furunculosis, or superficial cellulitis),
- •f)Self-limiting infections such as isolated folliculitis or other infection that has a high surgical incision cure rate or furunculosis or carbunculosis that is not associated with a cellulitis at least 1 cm in radius,
- •g)Skin and/or skin structure infection that can be treated by surgery alone,
- •h)Infections associated with a prosthetic device, and
- •i)Suspected or confirmed osteomyelitis.
- •2.Known or suspected concurrent infection or conditions requiring systemic anti infective treatment, prophylaxis, or suppression therapy (excluding ongoing suppression therapy for herpes simplex virus [HSV]);
- •3.Known or suspected human immunodeficiency virus (HIV)-infected patients with a cluster of differentiation (CD4) count <350 cells/mm3 recorded in the last 30 to 60 days, or receiving highly active anti-retroviral therapy (HAART);
- •4.Absolute neutrophil count (ANC) £1000 cells/mm3;
- •5.Organ transplant patients having received a transplant within the last 6 months;
- •6.Received >24 hours’ coverage of Gram-positive pathogens by any systemic antibiotic or any topical antibiotic at the infection site within the last 7 days, unless there is evidence of treatment failure or documented resistance of Gram-positive pathogens to the previous antibiotic therapy;
- •7.cSSSI suspected or documented as being due exclusively to Gram-negative or anaerobic organisms based on epidemiological grounds or on direct examination of a specimen with Gram’s stain (mixed cSSSI in which both Gram-positive and Gram negative pathogens are isolated may be enrolled if the clinician suspects that the predominant causative pathogen is a Gram-positive organism);
- •8.Infections due to a Gram-positive organism known to be resistant to linezolid and/or mixed cSSSI in which the Gram-negative organisms are known to be resistant to aztreonam;
- •9.cSSSI known or suspected to be a fungal, parasitic or viral infection;
- •10.Concomitant morbidity of such severity that the patient is likely to die or present with serious medical conditions within 30 days of study entry;
- •11.Known or suspected local or systemic hypersensitivity to trimethoprim, linezolid, or related compounds;
- •12.Morbid obesity defined as a body mass index >40 or weight >150 kg;
- •13.Pregnant or breast-milk feeding female;
- •14.Severe renal impairment with CrCL <30 mL/min:
- •15.Severe hepatic disease (Child-Pugh Class C) or known alanine transaminase (ALT) >5 times the upper limit of normal and/or bilirubin >1.5 times the upper limit of normal;
- •16.Requirement for steroids >10 mg/day, prednisone or equivalent, or received steroids >10 mg per day prednisone or equivalent in the past 3 days;
- •17.Cardiovascular conditions and treatments:
- •a)Patients known to have congenital or sporadic syndromes of QTc prolongation,
- •b)Type IA or III anti-arrhythmic drugs,
- •c)Nonsustained ventricular tachycardia (NSVT) defined as ³10 consecutive ventricular beats at a rate of >120 beats per minute (bpm) with a duration of <30 seconds,
- •d)Bradycardia (<50 bpm), and
- •e)QT/QTc interval outside the normal range defined as: QTc >450 ms.
- •18.Abnormal blood electrolyte
研究者
相似试验
进行中（未招募）
1 期
Phase 3, randomized, investigator-blind, multi-center study to evaluate efficacy and safety of intravenous iclaprim versus intravenous linezolid in complicated skin and skinstructure infections - ASSIST-2Complicated skin and skin structure infectionsMedDRA version: 8.1 Level: HLT Classification code 10040786 Term: Skin structures and soft tissue infectionsEUCTR2005-003630-18-GBArpida AG500
进行中（未招募）
不适用
ot-to-Lot Consistency Study of DTaP-IPV-Hep B-PRP-T Vaccine Administered at 2-4-6 Months of Age in Healthy Mexican InfantsPrevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus influenzae type b and infection caused by hepatitis B virusMedDRA version: 14.1Level: PTClassification code 10021430Term: ImmunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10036897Term: Prophylactic vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: HLTClassification code 10021431Term: ImmunisationsSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: HLGTClassification code 10043413Term: Therapeutic procedures and supportive care NECSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-004455-39-Outside-EU/EEASanofi Pasteur S.A1,190
进行中（未招募）
不适用
Phase III, multi-center, randomized, double blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab - Humira StudyMedDRA version: 10Level: LLTClassification code 10002556Term: <Manually entered code. Term in E.1.1>Juvenile ankylosing spondylitisEUCTR2007-003358-27-DECenter of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
已完成
3 期
ABDALA Clinical Study - Phase IIICOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000359Center for Genetic Engineering and Biotechnology (CIGB), in Havana.48,290
进行中（未招募）
3 期
Phase III, multi-center, randomized, double-blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with AdalimumabM08.1juvenile ankylosing spondylitisJuvenile ankylosing spondylitisDRKS00000071Asklepios Klinik Sankt Augustin32